Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer

• Conditions: Non-small Cell Lung Cancer

• Registration Number: NCT02075957
• Lead Sponsor: University Hospital, Angers

Brief Summary

Description of new transcriptional profiles associated with risk of relapse and identification of specific sites of relapse in non-small cell lung cancer, toxicity and resistance to adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC).

Detailed Description

* A first blood sample will be taken during the week before the operation. A second blood sample will be taken 4 to 8 weeks after the operation. And in case of relapse, a third sample will be taken. These samples are going to be stored in the collection of biological resources of Angers.

* Concerning the biopsy of the resected NSLCL, it will be sent to the collection of biological resources of Angers for conservation directly next to the surgery.

Study Timeline

• Study Start: 2013-10
• Status Verified: 2014-02
• Study First Submitted: 2014-02-11
• Study First Submitted QC: 2014-02-27
• Last Update Submitted: 2014-02-27
• Study First Posted: 2014-03-03
• Last Update Posted: 2014-03-03
• Primary Completion: 2016-01
• Study Completion: 2016-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 192

Inclusion Criteria

• Major subject
• Subject who received resection with primary non-small cell lung cancer at the University Hospital of Angers and whose tumor samples will be stored in collection of biological resources of University Hospital of Angers
• A written inform consent.

Exclusion Criteria

• Under 18 year old;
• Pregnant or nursing women;
• Deprived of liberty;
• Age under curatorship or guardianship;
• Unable to consent person;
• About not carrying a non-small cell lung cancer.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determination of news microarrays profiles of NSCLC relapse risks	At 10 years	The news microarrays profiles of NSCLC relapse risks will : * assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk); * assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient; * assessing the prediction of sites most likely metastatic relapse to guide survey strategy.

Trial Locations

Locations (1)

UH Angers; 🇫🇷 Angers, Maine et Loire, France